

Läkemedelsakademin

Swedish Academy of Pharmaceutical Sciences

in collaboration with:



Preliminary programme

Frontiers in Antibacterial Drug Discovery (FiADD)

September, 14-15, 2016, Stockholm, Sweden

Wednesday, September 14

08:45 *Registration, Coffee*

09:30 Opening & Welcome note

Session 1: Finding new chemical entities for antibacterials

Chair:

09:45 **Plenary lecture: a lack of novelty in the antibiotic pipeline**
Karen Bush, Indiana University, USA

10:30 **Antibiotic adjuvants: drug combinations that overcome resistance**
Gerry Wright, McMaster University, Canada

11:00 **Comprehensive metabolomics for the systematized discovery of antimicrobial agents from natural products**
Roger Linington, Simon Fraser University, Canada

11:30-12:00 *Coffee & Exhibition*

Session 2: Gram negative antibacterial entry

Chair:

12:00 **The role of membrane transport in antibiotic action and resistance**
Malcolm Page, Jacobs University Bremen, Germany

12:30 **Improved polymyxins for MDR gram-negative infections'**
Mike Dawson, Cantab Anti-infectives Ltd., England

13:00-14:30 *Lunch & Posters*

Session 3: Poster pitch session

Chair:

Basic Research

14:30-15:00 *Poster 1-4 (5 minutes each)*

Company pitches

15:00-15:15 Poster 5-7 (5 minutes each)

15:15 *Coffee Break*

Session 4: Alternatives to traditional antibiotics

Chair:

16:00 **Attacking virulence: a new approach for the treatment of bacterial infections**
Mike Pucci, Spero Therapeutics, USA

16:30 **Immune modulators and anti-biofilm agents as alternatives and adjuncts to antibiotics**
Bob Hancock, University of British Columbia, Canada

19:00- Conference Dinner

Thursday, September 15

Session 5: Antibacterial resistance

Chair:

8:30-9:15 **Plenary lecture: Antibiotic resistance as a drug target**
Fernando Baquero, Ramón y Cajal University, Spain

9:15-9:45 **Antimicrobial resistance. When two worlds collide**
Tim Walsh, Cardiff University, England

9:45-10:15 **Contribution of resistance study to the design, screening, and intelligent use of antibiotics**
Patrice Courvalin, Institut Pasteur, France

10:15-10:45 Coffee Break

Session 6: Economics and policy of drug discovery & development

Chair:

10:45-11:05 Speaker 11Tbd

11:05-11:25 Speaker 12 Enrico Baraldi, Sweden

11:25-11:45 Speaker 13 Tbd

11:45-12:15 Panel discussion

12:15-13:30 Lunch & Posters

Session 7: Industry experience of developing antibiotics

Chair:

13:30 -14:00 **Why we need to find alternative approaches to traditional antibiotics**
Steve Baker, GlaxoSmithKline, USA

14:00-14:30 **Progress in the design and development of a new class of antibiotics, primed for emerging superbugs**

Erin Duffy, Melinta Therapeutics, Inc, USA

14:30-15:00 **Improving our understanding of porin permeability in gram-negative bacteria**

Ruben Tommasi, Entasis Therapeutics, USA

15:00-15:30 **Discovery of avibactam: when chemistry meets biology**

Maxime Lampilas, Sanofi Aventis R&D, France

15:30-16:00 Coffee break

16:00 Poster award

16:10- Closing note